PTMA

PTMA (Prothymosin α) is a multifunctional, intrinsically charged nuclear and cytoplasmic protein that operates as a chromatin/chaperone factor and a regulator of mitochondrial and transcriptional programs across diverse cell types (PMID:40408476, PMID:40474236, PMID:41544148). In the nucleus, PTMA acts as a linker histone chaperone that promotes release of histone H1.0 from chromatin at sites of DNA damage and is required for efficient PARP1 recruitment, with PTMA-null cells failing to evict H1.0 and showing heightened sensitivity to DNA-damaging agents (PMID:40474236). PTMA also tunes chromatin-associated transcriptional output by binding MBD3 and inhibiting the deacetylase activity of the MBD3/HDAC1 NuRD complex, thereby raising STAT3 acetylation and phosphorylation to drive cardiomyocyte proliferation (PMID:40408476). In the mitochondrial/metabolic axis, PTMA binds the mitochondrial transcription factor TFAM to preserve mitochondrial DNA integrity and sustain oxidative phosphorylation in CD8 T cells—a function placed downstream of TCF1 and required for T cell persistence and the efficacy of PD-1 blockade (PMID:41544148)—and engages HMGB1 to support oxidative phosphorylation and restrain ROS accumulation and apoptosis in esophageal cancer cells (PMID:37065565). PTMA additionally acts downstream of TGFβ1 to modulate fibroblast proliferation and SMAD4-associated ECM production (PMID:29088825), and macrophage-derived phosphorylated PTMA can induce hyphal filamentation in Candida albicans (PMID:34433036).

1. 2017 Medium

   Established PTMA as a functional node in TGFβ1-driven fibrosis, addressing whether PTMA actively contributes to ECM production rather than being a passive marker.

   Evidence siRNA knockdown and overexpression in primary human oral submucous fibroblasts with proliferation and ECM marker readouts in a TGFβ1-induced fibrosis model

   PMID:29088825

   Open questions at the time

   • Direct molecular mechanism linking PTMA to SMAD4 not defined
   • Single lab, single primary cell type
   • No physical interaction with a TGFβ pathway component shown
2. 2021 Medium

   Showed that secreted/macrophage-derived phosphorylated PTMA has an extracellular bioactivity, identifying it as a host factor that drives Candida albicans hyphal filamentation.

   Evidence Bioactivity-guided fractionation with mass spectrometry, immunoneutralization, and enzymatic treatment in a C. albicans filamentation assay

   PMID:34433036

   Open questions at the time

   • Fungal receptor or target of PTMA unidentified
   • Phosphosite responsible for activity not mapped
   • Physiological relevance in vivo not established
3. 2023 Medium

   Defined a PTMA–HMGB1 interaction controlling mitochondrial oxidative phosphorylation, linking PTMA to redox and apoptotic balance in cancer cells.

   Evidence Reciprocal co-IP, immunofluorescence, siRNA knockdown with HMGB1 overexpression rescue, and multiple mitochondrial/ROS assays in ESCC cells

   PMID:37065565

   Open questions at the time

   • Mechanism by which the PTMA–HMGB1 complex regulates OXPHOS unresolved
   • Subcellular site of interaction not localized
   • Single lab
4. 2025 High

   Resolved a nuclear mechanism for PTMA as a linker histone chaperone, answering how H1.0 is displaced from damaged chromatin to permit PARP1 recruitment.

   Evidence Photoconvertible H1.0 live-cell imaging, Ptma-/- and Parp1-/- cells, dominant tight-binding H1.0 mutant, and DNA damage sensitivity assays

   PMID:40474236

   Open questions at the time

   • Structural basis of PTMA–H1.0 chaperoning not solved
   • Whether PTMA acts directly on H1 variants beyond H1.0 untested
   • Order/coupling of H1 release and PARP1 loading not fully dissected
5. 2025 High

   Connected PTMA to a chromatin-modifying transcriptional circuit, showing it inhibits NuRD deacetylase activity via MBD3 to amplify STAT3 signaling and drive cardiomyocyte proliferation.

   Evidence Co-IP, cardiomyocyte conditional knockout, AAV9 overexpression, and epistasis across mouse, rat, and human iPSC-derived cardiomyocytes

   PMID:40408476

   Open questions at the time

   • How PTMA binding inhibits HDAC1 catalysis mechanistically unclear
   • Whether the NuRD-STAT3 axis operates outside cardiomyocytes untested
6. 2026 High

   Identified a mitochondrial genome-protective role for PTMA via TFAM that sustains CD8 T cell oxidative metabolism and immunotherapy response, placing it downstream of TCF1.

   Evidence T cell-specific Ptma deletion, transcriptomics, PTMA-TFAM interaction studies, OXPHOS assays, and in vivo tumor models with PD-1 blockade

   PMID:41544148

   Open questions at the time

   • Structural/biochemical basis of PTMA–TFAM interaction not defined
   • How a predominantly nuclear protein accesses the mitochondrial matrix unresolved
   • Relationship between this TFAM role and the HMGB1-OXPHOS role unexplored

• How PTMA's distinct nuclear (H1.0/NuRD) and mitochondrial (TFAM/HMGB1) activities are coordinated, and what governs its partitioning between compartments and partners, remains unresolved.
• No unifying structural model across binding partners
• Determinants of subcellular targeting unknown
• Post-translational regulation (e.g., phosphorylation) linking functions uncharacterized